The latest GLP-1 weight loss drugs are generally approved for chronic weight management in adults with a BMI of 30 or higher and people with a BMI of 27 or higher who also have weight-related conditions like high blood pressure, type 2 diabetes, or high cholesterol
People who already have GLP-1 drugs covered through their Medicare Part D plan or have Type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible
Endocrinology 144 , 51455148 (2003)
Available from: Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, et al
The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimers disease
This means retatrutide does not rely solely on appetite suppression